- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Survey Shows Disconnect on End-of-Life Healthcare
Very few Californians have talked to their doctors about their end-of-life health care despite a desire to do so, according to a poll that revealed a wide disparity between how people want their final days to be handled and what they've done to ensure it.
The survey, released today by the California HealthCare Foundation, found that two-thirds of Californians said they would prefer a natural death if severely ill and just 7 percent wanted all possible care to prolong their lives.
And it also showed broad public support for reimbursing physicians who take the time to talk to them about their end-of-life options, the very issue that sparked the infamous "death panel" debate in 2009 over President Obama's federal health care legislation.
Above all, results revealed a glaring need for doctors to talk to their patients about their options, and for people in general to make their wishes known to those who will have to make decisions about their care.
Read more at: http://tinyurl.com/7jbeede
Source: San Francisco Chronicle
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
